Welcome to our dedicated page for Amarin Plc news (Ticker: $AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin Plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amarin Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amarin Plc's position in the market.
Amarin plc (NASDAQ: AMRN) will have their president and CEO, Patrick Holt, participate in a fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20th, 2024, in NYC. The session will be webcast live and archived on the Company’s website.
Amarin plc (NASDAQ:AMRN) reported its first-quarter 2024 business update and financial results. The company received a new patent extending intellectual property protection in Europe until 2039. While the U.S. market saw a decline in revenue due to generic competition, the European market experienced significant growth. Amarin also announced a share repurchase program and remains stable with a cash position of $308 million. Overall, the company is focused on enhancing its value for the future.
